working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the post will be close or bad ...
nothing, is the excuse of all message boards in all stocks
https://clinicaltrials.gov/ct2/results?term=brilacidin
first the start of the test must be published...
I think they have 21 days to do it from the start
we are on the way,
we have had a lot of patience so far,
now is the time to hold on and enjoy the trip, despite the attacks we will suffer along the way
our news is more than proven
someday "before the market opens" we will have the news we expect and then there will be no time to move
...In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation was successfully completed. Planning for a Phase 2 clinical trial is underway. The Company is eligible to receive $24 million in upfront and milestone payments, and a 6 percent royalty (net sales) upon the successful marketing of Brilacidin for UP/UPS....
A Phase 2 clinical trial of intravenously-administered Brilacidin for COVID-19 is currently underway in the United States and Russia. The study is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of Brilacidin in COVID-19 hospitalized patients. Target enrollment is 120 patients. Regulatory approvals have been obtained from the respective country’s Health Authorities for conducting this study.
Active Clinical Development Programs
Compound Target/Indication Clinical Status
Brilacidin COVID-19 Phase 2 Study
10Q:... In February 2021, the clinical trial of Brilacidin for treating hospitalized patients with COVID-19 in the United States and Russia began with patients being recruited to the study.
10 Q:...In December 2020, the U.S. Food and Drug Administrations (FDA) approved the Company’s Investigational New Drug (IND) application to proceed with initiation of a randomized, placebo-controlled Phase 2 clinical trial of Brilacidin in moderate-to-severe hospitalized patients with COVID-19. Similar regulatory approval was obtained from the Russian Ministry of Health.
the last change always greater than the ASK,
we don't really know the date it started,
then the disappointment is worse IMO
all very red, day to be calm,
tomorrow will be another day
the whole market is very, very red
"I believe expectations and then I am disappointed"
but these expectations I have created alone,
the company will present the 10Q
nothing else has the company said
the rest, because that "the game"
what's up? only Russia imports,
pure manipulation and speculation
well ..., I am calm, I am loaded from below, I am not in a hurry and the cuts do not scare me
I have been here more than a year and it never went up like now, organized and with such a level of accumulation
all very organized, I like ...
Wasn't it Aspire? LOL 0.48
where is the next wall? LOL 0.45 $ out, and 46 and 47 ...
all very organized, calculated ...
I am Spanish, it was after the first dose, it takes 2 and then 7 more days for immunity
LOOOOOOOOOOOOOLLLLLLL brick wall
that's right
it could also be today...
...and in particular, developments on or around the filing due date relating to clinical trials in the United States and Russia.
yesterday more information than necessary in the NT,
now suddenly it is discovered that tests are actually being carried out in Russia
coincidence? I don´t believe
next days will be interesting
was a filing and a PR all in one...
Dangerous to be out now, soon booommm
10Q could come "warm"
...in preparing disclosure relating to recent developments regarding clinical trials for the Registrant’s lead drug compound, and in particular, developments on or around the filing due date relating to clinical trials in the United States and Russia...
BID gradually increasing
IPIX
seems to be time for another upward leg
IPIX
if everything goes well...
Merger-acquisition is the only way out here, the question is "when" can be more profitable for the company or when it is essential for the company
the problem is creating expectations without any foundation (the same thing every day: news, news, news ...)
nobody knows when we will have news,
too much speculation